Howard H. Bailey

5.6k total citations
108 papers, 4.2k citations indexed

About

Howard H. Bailey is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Howard H. Bailey has authored 108 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 35 papers in Molecular Biology and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Howard H. Bailey's work include Cancer Treatment and Pharmacology (19 papers), Sulfur Compounds in Biology (9 papers) and Lymphoma Diagnosis and Treatment (8 papers). Howard H. Bailey is often cited by papers focused on Cancer Treatment and Pharmacology (19 papers), Sulfur Compounds in Biology (9 papers) and Lymphoma Diagnosis and Treatment (8 papers). Howard H. Bailey collaborates with scholars based in United States, Spain and Malaysia. Howard H. Bailey's co-authors include Ríona Mulcahy, Jerry J. Gipp, Hasan Mukhtar, George Wilding, Jeremy J. Johnson, Dona Alberti, Marcia Pomplun, Rick Chappell, Nihal Ahmad and Cameron O. Scarlett and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Howard H. Bailey

103 papers receiving 4.1k citations

Peers

Countries citing papers authored by Howard H. Bailey

Since Specialization

Citations

This map shows the geographic impact of Howard H. Bailey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard H. Bailey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard H. Bailey more than expected).

Fields of papers citing papers by Howard H. Bailey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard H. Bailey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard H. Bailey. The network helps show where Howard H. Bailey may publish in the future.

Co-authorship network of co-authors of Howard H. Bailey

This figure shows the co-authorship network connecting the top 25 collaborators of Howard H. Bailey. A scholar is included among the top collaborators of Howard H. Bailey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard H. Bailey. Howard H. Bailey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	National Analysis of More Than 48,000 Veterans With HIV Demonstrates CD4/CD8 Ratio as a Risk Marker for Anal Intraepithelial Lesions and Anal Cancer 2025 ·Diseases of the Colon & Rectum ·(unknown), (unknown), (unknown), Howard H. Bailey, Evie H. Carchman, Rob Striker, (unknown)	0
2	Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery 2024 ·Cancer Prevention Research ·(unknown), Howard H. Bailey, (unknown), (unknown), (unknown), Cameron O. Scarlett, Thomas C. Havighurst, (unknown), (unknown), (unknown), Trinity J. Bivalacqua, Daniel R. Saltzstein, Neal D. Shore, KyungMann Kim, Wei Huang, William A. Ricke, Lisa Barroilhet, (unknown), Howard L. Parnes, Edward M. Messing	1
3	Non-melanoma skin cancer event rates in a formalized clinical trial setting: considerations for clinical trial design 2023 ·European Journal of Cancer Prevention ·(unknown), KyungMann Kim, Thomas C. Havighurst, Gary S. Wood, Jill Kolesar, Howard H. Bailey	1
4	A phase II randomized placebo‐controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance 2020 ·The Prostate ·David F. Jarrard, (unknown), Wei Huang, (unknown), (unknown), KyungMann Kim, Badrinath R. Konety, Daniel R. Saltzstein, Hasan Mukhtar, (unknown), Chen S. Suen, (unknown), Howard L. Parnes, Howard H. Bailey	24
5	Stillbirth in women living with HIV delivering in the UK and Ireland: 2007-2015 2019 ·UCL Discovery (University College London) ·Graziella Favarato, (unknown), Helen Peters, Rebecca Sconza, Howard H. Bailey, (unknown), P Tookey, Claire Thorne	0
6	A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers 2019 ·Cancer Prevention Research ·Jill Kolesar, (unknown), Heather Green, (unknown), (unknown), (unknown), Douglas Laux, Helen Krontiras, Donald D. Muccio, KyungMann Kim, Clinton J. Grubbs, (unknown), Howard L. Parnes, Brandy M. Heckman‐Stoddard, Howard H. Bailey	5
7	American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention 2016 ·Journal of Clinical Oncology ·Howard H. Bailey, Linus Chuang, Nefertiti C. duPont, Cathy Eng, Lewis E. Foxhall, Janette K. Merrill, Dana S. Wollins, Charles D. Blanke	60
8	Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer 2015 ·Cancer Prevention Research ·Carol J. Fabian, Bruce F. Kimler, Carola M. Zalles, Teresa A. Phillips, Trina Metheny, Brian K. Petroff, Thomas C. Havighurst, KyungMann Kim, Howard H. Bailey, Brandy M. Heckman‐Stoddard	14
9	Inpatient Hospitalization of Oncology Patients: Are We Missing an Opportunity for End-of-Life Care? 2013 ·Journal of Oncology Practice ·Gabrielle B. Rocque, (unknown), (unknown), Jens C. Eickhoff, Howard H. Bailey, Toby C. Campbell, James A. Stewart, James F. Cleary	85
10	A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies 2013 ·Investigational New Drugs ·William R. Schelman, Anne M. Traynor, Kyle D. Holen, Jill Kolesar, Steven Attia, Tien Hoang, Jens C. Eickhoff, Zhisheng Jiang, Dona Alberti, Rebecca Marnocha, Joel M. Reid, Matthew M. Ames, Renee M. McGovern, Igor Espinoza‐Delgado, James R. Wright, George Wilding, Howard H. Bailey	24
11	Enhancing the bioavailability of resveratrol by combining it with piperine 2011 ·Molecular Nutrition & Food Research ·Jeremy J. Johnson, Minakshi Nihal, Imtiaz A. Siddiqui, Cameron O. Scarlett, Howard H. Bailey, Hasan Mukhtar, Nihal Ahmad	278
12	A Systemic Hyperthermia Oncologic Working Group Trial 2003 ·Oncology ·Anneke M. Westermann, G. Wiedemann, Elke Jäger, Dirk Jäger, Dörthe M. Katschinski, Alexander Knuth, P. Zum Vörde Sive Vörding, J.D.P. van Dijk, (unknown), Antje Neumann, (unknown), (unknown), (unknown), (unknown), Howard H. Bailey, S. Peters, H. Ian Robins	23
13	Phase I trial of perillyl alcohol administered four times daily continuously 2003 ·Cancer Chemotherapy and Pharmacology ·(unknown), Sarita Dubey, Michael N. Gould, Kendra D. Tutsch, Rebecca Marnocha, (unknown), Dona Alberti, (unknown), Chris Feierabend, Jennifer Volkman, (unknown), Sandra E. Black, Marcia Pomplun, George Wilding, Howard H. Bailey	21
14	Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2 2002 ·Genetic Testing ·Ellen M. Hartenbach, (unknown), Elizabeth A. Grosen, Howard H. Bailey, Daniel G. Petereit, Renata Laxová, Julian C. Schink	8
15	Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol 2002 ·Cancer Chemotherapy and Pharmacology ·James P. Thomas, Kendra D. Tutsch, James F. Cleary, Howard H. Bailey, Rhoda Arzoomanian, Dona Alberti, (unknown), Chris Feierabend, (unknown), Rebecca Marnocha, Amy Dresen, George Wilding	100
16	Phase I Study of Eniluracil, Oral 5-Fluororacil and Gemcitabine in Patients with Advanced Malignancy 2002 ·Investigational New Drugs ·(unknown), James P. Thomas, Daniel Mulkerin, Jordan Berlin, Howard H. Bailey, Kim Binger, Jennifer Volkman, Dona Alberti, Chris Feierabend, (unknown), Rhoda Arzoomanian, George Wilding	2
17	Phase I clinical and pharmacokinetic trial of irofulven 2001 ·Cancer Chemotherapy and Pharmacology ·James Thomas, Rhoda Arzoomanian, Dona Alberti, Chris Feierabend, (unknown), Kendra D. Tutsch, Thomas E. Steele, Rebecca Marnocha, Charlotte G. Smith, Sheri L. Smith, John R. MacDonald, George Wilding, Howard H. Bailey	16
18	Increased expression of γ-glutamyl transpeptidase in transfected tumor cells and its relationship to drug sensitivity 1994 ·Cancer Letters ·Howard H. Bailey, Jerry J. Gipp, Ríona Mulcahy	14
19	A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions 1992 ·Cancer Chemotherapy and Pharmacology ·Howard H. Bailey, George Wilding, Kendra D. Tutsch, Rhoda Arzoomanian, Dona Alberti, Mary Beth Tombes, Jean L. Grem, David R. Spriggs	2
20	Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion. 1991 ·PubMed ·Howard H. Bailey, K D Tutsch, R Z Arzoomanian, Mary Beth Tombes, Dona Alberti, (unknown), (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact